Iopromide

Summary

Iopromide (CHEMBL1725) is an approved small-molecule nephrotoxic agent (ATC V08AB05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB05
• Clinical trials: 9
• Chemistry: 791.1 Da · C18H24I3N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1725
Name	Iopromide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3736
ChEBI	CHEBI:63578
ATC	V08AB05
Molecular formula	C18H24I3N3O8
Molecular weight	791.1
InChIKey	DGAIEPBNLOQYER-UHFFFAOYSA-N

SMILES: CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I

IUPAC name: 1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-3-N-methylbenzene-1,3-dicarboxamide

ChEBI definition: A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.

Pharmacological roles (ChEBI): radioopaque medium, nephrotoxic agent.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Iopromida, Iopromide, Proscope, Ultravist, Ultravist (pharmacy bulk), Ultravist 150, Ultravist 240, Ultravist 300, Ultravist 370, ZK 35760, ZK-35760, IOPROMIDE

Patent coverage: 2,367 distinct patent families (7,411 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,410 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00335101	PHASE4	WITHDRAWN	Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
NCT00827788	PHASE4	COMPLETED	Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
NCT00926562	PHASE4	COMPLETED	A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients
NCT01255722	PHASE4	COMPLETED	Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
NCT01580046	PHASE4	UNKNOWN	Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction
NCT03631771	PHASE4	WITHDRAWN	Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT01654354	Not specified	COMPLETED	Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT
NCT01703650	Not specified	UNKNOWN	Role of Perfusion CT in Pancreatic Cancer
NCT07391787	Not specified	COMPLETED	Low-acid Contrast Media for Preventing Post ERCP Pancreatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).